These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 37133514)

  • 1. 68Ga-PSMA PET/CT Detecting Metastatic Lesion of RCC: Missed on 18F-FDG PET/CT.
    Jha S; Hemrom A; Shamim SA; Barwad A; Batra A
    Clin Nucl Med; 2023 Jun; 48(6):e294-e296. PubMed ID: 37133514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of
    Aggarwal P; Singh H; Das CK; Mavuduru RS; Kakkar N; Lal A; Gorsi U; Kumar R; Mittal BR
    Eur J Radiol; 2024 Jan; 170():111218. PubMed ID: 38007857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Head-to-head comparisons of enhanced CT, 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in identifying adverse pathology of clear-cell renal cell carcinoma: a prospective study.
    Chen SH; Lin BH; Chen SM; Qiu QR; Ruan ZT; Chen ZJ; Wei Y; Zheng QS; Xue XY; Miao WB; Xu N
    Int Braz J Urol; 2023; 49(6):716-731. PubMed ID: 37624658
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Parghane RV; Basu S
    J Nucl Med Technol; 2023 Sep; 51(3):261-262. PubMed ID: 36041875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of dual tracer PSMA and FDG PET/CT in renal cell carcinoma (RCC) compared to conventional imaging: A multi-institutional case series with intra-individual comparison.
    Tariq A; Kwok M; Pearce A; Rhee H; Kyle S; Marsh P; Raveenthiran S; Wong D; McBean R; Westera J; Dunglison N; Esler R; Navaratnam A; Yaxley JW; Thomas P; Pattison DA; Roberts MJ
    Urol Oncol; 2022 Feb; 40(2):66.e1-66.e9. PubMed ID: 34895817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [
    Lin R; Wang C; Chen S; Lin T; Cai H; Chen S; Yang Y; Zhang J; Xu F; Zhang J; Chen X; Zang J; Miao W
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):535-547. PubMed ID: 37728667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 68Ga-PSMA PET/CT and 18F-FDG PET/CT in Renal Cell Carcinoma.
    Chen EJ; Tan TH; Chew MT; Chye PC
    Clin Nucl Med; 2020 Jul; 45(7):e317-e319. PubMed ID: 32404702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary Role of 68Ga-Prostate-Specific Membrane Antigen and 18F-FDG PET/CT for Evaluation of Metastases and Treatment Response in Renal Cell Carcinoma.
    Has Simsek D; Civan C; Erdem S; Sanli Y
    Clin Nucl Med; 2021 Jul; 46(7):579-581. PubMed ID: 33782292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incremental Value of 18F-PSMA-1007 PET/CT in Detection of Metastatic Renal Cell Carcinoma to the Brain.
    Sadeq A; Usmani S; Esmail AA; Fathallah W; Alfeeli MA; Marafi F
    Clin Nucl Med; 2022 Jul; 47(7):627-628. PubMed ID: 35675136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of
    Siva S; Callahan J; Pryor D; Martin J; Lawrentschuk N; Hofman MS
    J Med Imaging Radiat Oncol; 2017 Jun; 61(3):372-378. PubMed ID: 28116853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 18F-FDG and 68GA-Prostate-Specific Membrane Antigen PET/CT Perform Better Than CT Alone in Restaging Papillary Renal Cell Carcinoma Recurrence.
    Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Silini EM; Ruffini L
    Clin Nucl Med; 2021 Sep; 46(9):e458-e460. PubMed ID: 34374683
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complimentary Pattern of Uptake in 18F-FDG PET/CT and 68Ga-Prostate-Specific Membrane Antigen PET/CT in a Case of Metastatic Clear Cell Renal Carcinoma.
    Sasikumar A; Joy A; Nanabala R; Unni M; Tk P
    Clin Nucl Med; 2016 Dec; 41(12):e517-e519. PubMed ID: 27749421
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Qi Z; Yao X; Su M; Huang R
    Hell J Nucl Med; 2023; 26(2):155-156. PubMed ID: 37527052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Superiority of 68Ga-FAPI-04 in Delineation of Soft Tissue and Liver Metastases in Chromophobe Renal Cell Carcinoma for Restaging.
    Xie F; Fu L; Zhou W
    Clin Nucl Med; 2022 Dec; 47(12):e758-e759. PubMed ID: 36342807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inconsistent Detection of Sites of Metastatic Non-Clear Cell Renal Cell Carcinoma with PSMA-Targeted [
    Yin Y; Campbell SP; Markowski MC; Pierorazio PM; Pomper MG; Allaf ME; Rowe SP; Gorin MA
    Mol Imaging Biol; 2019 Jun; 21(3):567-573. PubMed ID: 30218388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-PSMA-1007 PET/CT for Initial Staging of Renal Cell Carcinoma in an End-Stage Renal Disease Patient.
    Marafi F; Sasikumar A; Aldaas M; Esmail A
    Clin Nucl Med; 2021 Jan; 46(1):e65-e67. PubMed ID: 33181733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.
    Karivedu V; Jain AL; Eluvathingal TJ; Sidana A
    Curr Urol Rep; 2019 Aug; 20(10):56. PubMed ID: 31468240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of PSMA PET/CT in Staging and Restaging of Renal Cell Carcinoma: A Systematic Review and Metaanalysis.
    Sadaghiani MS; Baskaran S; Gorin MA; Rowe SP; Provost JC; Teslenko I; Bilyk R; An H; Sheikhbahaei S
    J Nucl Med; 2024 Jul; 65(7):1007-1012. PubMed ID: 38782453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergic role of dual tracer PET/CT with
    Gasparro D; Scarlattei M; Manuguerra R; Guglielmo P; Migliari S; Sammartano A; Baldari G; Maestroni U; Ruffini L
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(5):322-324. PubMed ID: 36100315
    [No Abstract]   [Full Text] [Related]  

  • 20. Special issue "The advance of solid tumor research in China": 68Ga-PSMA-11 PET/CT for evaluating primary and metastatic lesions in different histological subtypes of renal cell carcinoma.
    Li Y; Zheng R; Zhang Y; Huang C; Tian L; Liu R; Liu Y; Zhang Z; Han H; Zhou F; He L; Dong P
    Int J Cancer; 2023 Jan; 152(1):42-50. PubMed ID: 35751420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.